Acumen Pharmaceuticals, Inc. (ABOS) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Acumen Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Highlights
November 14, 2022 4:01 PM ESTINTERCEPT-AD, a Phase 1 clinical trial of ACU193 in patients with early Alzheimers disease continues to progress
Acumen anticipates completing enrollment in the first quarter of 2023 and reporting topline data from this trial in the second half of 2023
ACU193 was granted Fast Track designation from the U.S. FDA for the treatment of early Alzheimers disease
Cash, cash equivalents and marketable securities of $200.2 million as of Sept. 30, 2022 expected to be sufficient to support clinical and operational goals through 2025
Company to host conference call and webcast today at... More
